AGS-16C3F

DB17551InvestigationalProtein Based Therapies

AGS 16C3F is an intravenously administered, anti-ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3) antibody-drug conjugate. AGS-16C3F is under investigation in clinical trial NCT02639182 (A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell...

Mechanism: Pharmacologically active on Ectonucleotide pyrophosphatase/phosphodiesterase family member 3
Curator reviewed
Code names: AGS-16C3F

Resolves to

Compound

UNIIVC1D38AGN9

Targets

O14638ENPP3

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with AGS-16C3F, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account